Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPEAT trial of regorafenib plus paclitaxel in advanced oesophagogastric cancer
NL-OMON47541Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of regorafenib and paclitaxel in esophageal cancer, gastric cancer (GC) and esophagogastric junction cancer (5 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Toxicity. Started Jul 2015; status: active, not recruiting.
02
Drugs
regorafenibpaclitaxel
03
Conditions
esophageal cancergastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on NL-OMON47541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47541.